Halozyme partners with GSK for subcutaneous cancer drug development
Go back to Halozyme partners with GSK for subcutaneous cancer drug development| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 68.88 +0.33 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.55 | 52 Week High | $18.39 | |||
| Open | $69.34 | 52 Week Low | $6.96 | |||
| Day High | $69.81 | P/E | N/A | |||
| Day Low | $68.78 | EPS | $-0.58 | |||
| Volume | 93,233 | |||||
